Drug Trial Radar · NCT04956302
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Sep 27, 2021
Primary completion
Jun 16, 2022
Study completion Jun 16, 2022
Sponsor
- Lead sponsor
- Abdullah KhanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth. Giving panobinostat in combination with daratumumab, bortezomib and dexamethasone may work better in treating relapsed/refractory multiple myeloma.
Conditions
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
Interventions
BortezomibDrug
Given SC
Daratumumab and Hyaluronidase-fihjDrug
Given SC
DexamethasoneDrug
Given PO or IV
Panobinostat LactateDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase 2 doseTime frame: End of cycle 1 (1 cycle = 28 days)
- Incidence of adverse eventsTime frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.